ScienceGate
Advanced Search
Author Search
Journal Finder
Blog
Sign in / Sign up
ScienceGate
Search
Author Search
Journal Finder
Blog
Sign in / Sign up
Faculty Opinions recommendation of Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
◽
10.3410/f.726024829.793532783
◽
2017
◽
Author(s):
John Wingard
◽
Maxim Norkin
Keyword(s):
Filamentous Fungi
◽
Primary Treatment
◽
Phase 3
◽
Randomised Controlled
Download Full-text
Related Documents
Cited By
References
Faculty Opinions recommendation of Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
◽
10.3410/f.726024829.793512570
◽
2015
◽
Author(s):
Neil Ampel
Keyword(s):
Filamentous Fungi
◽
Primary Treatment
◽
Phase 3
◽
Randomised Controlled
Download Full-text
Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial
The Lancet
◽
10.1016/s0140-6736(15)01159-9
◽
2016
◽
Vol 387
(10020)
◽
pp. 760-769
◽
Cited By ~ 367
Author(s):
Johan A Maertens
◽
Issam I Raad
◽
Kieren A Marr
◽
Thomas F Patterson
◽
Dimitrios P Kontoyiannis
◽
...
Keyword(s):
Filamentous Fungi
◽
Primary Treatment
◽
Phase 3
◽
Randomised Controlled
Download Full-text
Efficacy and safety outcomes in patients with probable or proven versus possible invasive mould disease from the phase 3 secure study, evaluating isavuconazole versus voriconazole for the primary treatment of invasive fungal disease caused by Aspergillus spp. or other filamentous fungi
10.26226/morressier.56d5ba24d462b80296c949e9
◽
2016
◽
Author(s):
Johan Maertens
Keyword(s):
Filamentous Fungi
◽
Invasive Fungal Disease
◽
Primary Treatment
◽
Fungal Disease
◽
Efficacy And Safety
◽
Phase 3
◽
Safety Outcomes
Download Full-text
Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial
The Lancet
◽
10.1016/s0140-6736(21)00219-1
◽
2021
◽
Vol 397
(10273)
◽
pp. 499-509
Author(s):
Johan A Maertens
◽
Galia Rahav
◽
Dong-Gun Lee
◽
Alfredo Ponce-de-León
◽
Isabel Cristina Ramírez Sánchez
◽
...
Keyword(s):
Invasive Aspergillosis
◽
Primary Treatment
◽
Phase 3
◽
Randomised Controlled
Download Full-text
Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised controlled, open-label, blinded-endpoints, phase 3 trial
The Lancet
◽
10.1016/s0140-6736(18)32003-8
◽
2019
◽
Vol 393
(10176)
◽
pp. 1128-1137
◽
Cited By ~ 29
Author(s):
Hiromichi Hamada
◽
Hiroyuki Suzuki
◽
Yoshihiro Onouchi
◽
Ryota Ebata
◽
Masaru Terai
◽
...
Keyword(s):
Coronary Artery
◽
Kawasaki Disease
◽
Intravenous Immunoglobulin
◽
Primary Treatment
◽
Open Label
◽
Phase 3
◽
Coronary Artery Abnormalities
◽
Increased Risk
◽
Randomised Controlled
Download Full-text
Faculty Opinions recommendation of Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
◽
10.3410/f.1166102.628092
◽
2009
◽
Author(s):
Jim Orr
◽
Fadi Abu Shahin
Keyword(s):
Ovarian Cancer
◽
Randomised Controlled Trial
◽
Controlled Trial
◽
Advanced Ovarian Cancer
◽
Open Label
◽
Phase 3
◽
Dose Dense
◽
Randomised Controlled
Download Full-text
Faculty Opinions recommendation of Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
◽
10.3410/f.13827960.15267062
◽
2012
◽
Author(s):
Weijing Sun
◽
Davendra Sohal
Keyword(s):
Gastric Cancer
◽
Randomised Controlled Trial
◽
Controlled Trial
◽
Open Label
◽
Phase 3
◽
D2 Gastrectomy
◽
Randomised Controlled
Download Full-text
Faculty Opinions recommendation of Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
◽
10.3410/f.717969433.793480577
◽
2013
◽
Author(s):
Nancy Lin
◽
Ines Vaz-Luis
Keyword(s):
Breast Cancer
◽
Early Stage
◽
Her2 Positive
◽
Phase 3
◽
Her2 Positive Breast Cancer
◽
Randomised Controlled
◽
Positive Breast Cancer
Download Full-text
Faculty Opinions recommendation of Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
◽
10.3410/f.718302523.793494710
◽
2014
◽
Author(s):
Anthony Harries
Keyword(s):
Randomised Controlled Trial
◽
Clinical Outcomes
◽
Antiretroviral Treatment
◽
Controlled Trial
◽
Phase 3
◽
Delayed Initiation
◽
Randomised Controlled
◽
Hiv 1
Download Full-text
Faculty Opinions recommendation of Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
◽
10.3410/f.725797184.793534680
◽
2017
◽
Author(s):
Wee Joo Chng
Keyword(s):
Retinoic Acid
◽
Arsenic Trioxide
◽
Acute Promyelocytic Leukaemia
◽
Acid Treatment
◽
Risk Groups
◽
Retinoic Acid Treatment
◽
Phase 3
◽
Trans Retinoic Acid
◽
All Trans Retinoic Acid
◽
Randomised Controlled
Download Full-text
Sign in / Sign up
Close
Export Citation Format
Close
Share Document
Close